Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.45 |
| ▸ | HRH2 | P25021 | 6/20 | 0.45 |
| ▸ | HRH1 | P35367 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523526 | 1.00 | P2RY12 (0.45) | P2RY12HRH2HRH1LMNAPOLB | |
| SCHEMBL523527 | 1.00 | P2RY12 (0.45) | P2RY12HRH2HRH1LMNAPOLB | |
| SCHEMBL31192233 | 1.00 | P2RY12 (0.45) | P2RY12HRH2HRH1LMNAPOLB | |
| SCHEMBL1111134 | 0.92 | CYP1A2 (0.40) | P2RY12HRH2HRH1LMNA | |
| SCHEMBL1111139 | 0.92 | CYP1A2 (0.40) | P2RY12HRH2HRH1LMNA | |
| SCHEMBL1111141 | 0.92 | CYP1A2 (0.40) | P2RY12HRH2HRH1LMNA | |
| SCHEMBL29165043 | 0.90 | P2RY12 (0.44) | P2RY12HRH2HRH1 | |
| SCHEMBL30888819 | 0.90 | P2RY12 (0.44) | P2RY12HRH2HRH1 | |
| SCHEMBL524046 | 0.85 | HRH2 (0.50) | P2RY12HRH2HRH1LMNAPOLB | |
| SCHEMBL524045 | 0.85 | HRH2 (0.50) | P2RY12HRH2HRH1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2225253-B1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | P2RY12 1/4885HRH2 604/4885HRH1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.